Overview

Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.

Eligibility

Inclusion Criteria:

• Controls underwent physical examinations or primary NPC cases confirmed by pathology or cytology.
• If cases, at stage I-IVB diagnosed by radiology according to AJCC/UICC 8th.
• If cases, Karnofsky score (KFS)≥70, estimated survival span>12 months.
• If cases, no disordered of major organs is found; blood test, liver, and kidney functions are basically normal.
• If cases, at least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1.

Exclusion Criteria:

• History of other malignant diseases.
• History of severe systemic diseases or heart, lung, liver, or kidney disfunction.
• History of severe neurological, metal, endocrine diseases.
• History of HBV, HCV, HIV, TP, or TB infection.
• If controls, physical examination reveals systemic diseases including malignant diseases.
• If cases, incomplete blood and pathological sample data.
• If cases, not receiving primary treatment in this facility.
• Other individuals investigators find not suitable for the trial.